ArticleInternational journal of molecular sciences2021
Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Prognostic potential of lipid profiling in cancer patients: a systematic review of mass spectrometry-based studies.Lipids in health and disease · 2024Pooled it
- Smoking-Stratified Signal Decomposition and Feature Selection for Never-Smoker Cancer Classification in a Combined Lung-Breast Metabolomics Cohort.International journal of molecular sciences · 2026Article
- Flow-cytometric profiling of large extracellular vesicles as immunophenotypic biomarkers in head and neck squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- The metabolome of fecal extracellular vesicles in patients with malignant solid tumors.Scientific reports · 2025Article
- Metabolomic Analysis of Breast Cancer in Colombian Patients: Exploring Molecular Signatures in Different Subtypes and Stages.International journal of molecular sciences · 2025Article
- Role of Liquid Biopsy for Early Detection, Prognosis, and Therapeutic Monitoring of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- Application of Metabolic Biomarkers in Breast Cancer: A Literature Review.Annals of laboratory medicine · 2025Review
- Discovery of Plasma Lipids as Potential Biomarkers Distinguishing Breast Cancer Patients from Healthy Controls.International journal of molecular sciences · 2024Article
- Biochemical Pathways Delivering Distinct Glycosphingolipid Patterns in MDA-MB-231 and MCF-7 Breast Cancer Cells.Current issues in molecular biology · 2024Review
- Extracellular vesicle-mediated drug delivery in breast cancer theranostics.Discover oncology · 2024Review
- Modulatory effects of cancer stem cell-derived extracellular vesicles on the tumor immune microenvironment.Frontiers in immunology · 2024Review
- Metabolic features of tumor-derived extracellular vesicles: challenges and opportunities.Extracellular vesicles and circulating nucleic acids · 2024Review
- Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring.Frontiers in oncology · 2024Review
- Integrative metabolomics science in Alzheimer's disease: Relevance and future perspectives.Ageing research reviews · 2023Review
- Review
- Comprehensive serum lipidomic analyses reveal potential biomarkers for malignant breast cancer: A case-control study.Cancer biomarkers : section A of Disease markers · 2023Article
- Extracellular vesicles in the treatment and diagnosis of breast cancer: a status update.Frontiers in endocrinology · 2023Review
- EASY-FIA: A Readably Usable Standalone Tool for High-Resolution Mass Spectrometry Metabolomics Data Pre-Processing.Metabolites · 2022Article
- Metabolomics of Extracellular Vesicles: A Future Promise of Multiple Clinical Applications.International journal of nanomedicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Malignant cells differ from benign ones in their metabolome and it is largely unknown whether this difference is reflected in the metabolic profile of their microvesicles (MV), which are secreted into the blood of cancer patients. Here, they are present together with MV from the various blood and endothelial cells. Harvesting MV from 78 breast cancer patients (BC) and 30 controls, we characterized the whole blood MV metabolome using targeted and untargeted mass spectrometry. Especially (lyso)-phosphatidylcholines and sphingomyelins were detected in a relevant abundance. Eight metabolites showed a significant discriminatory power between BC and controls. High concentrations of lysoPCaC26:0 and PCaaC38:5 were associated with shorter overall survival. Comparing BC subtype-specific metabolome profiles, 24 metabolites were differentially expressed between luminal A and luminal B. Pathway analysis revealed alterations in the glycerophospholipid metabolism for the whole cancer cohort and in the ether lipid metabolism for the molecular subtype luminal B. Although this mixture of blood-derived MV contains only a minor number of tumor MV, a combination of metabolites was identified that distinguished between BC and controls as well as between molecular subtypes, and was predictive for overall survival. This suggests that these metabolites represent promising biomarkers and, moreover, that they may be functionally relevant for tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.